BioNTech Calls Virtual 2026 AGM, Seeks Larger Supervisory Board to Back Oncology Push
End of Quarter Sale - 50% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
BioNTech SE ( (BNTX) ) has issued an announcement.
BioNTech SE disclosed in an April 2, 2026 Form 6-K that it has convened its 2026 Annual General Meeting for May 15, 2026, to be held virtually without physical shareholder attendance, with participation and voting to occur via an online Investor Portal and electronic absentee voting. The AGM will present the 2025 financial statements and compensation report, propose carrying forward the full 2025 balance sheet profit of roughly €6.9 billion, and seek shareholder approvals on management and supervisory board actions and the reappointment of EY as auditor.
In a move that underscores its growth and oncology-focused transformation, BioNTech is asking shareholders to amend its Articles of Association to expand the Supervisory Board from six to eight members, citing the need for broader expertise in oncology, marketing and clinical development. The company plans to fill the two new seats with industry experts, aiming to strengthen oversight and support for its strategic realignment, while the virtual, publicly broadcast AGM format is designed to accommodate global shareholders and ADS holders and maintain broad transparency.
The most recent analyst rating on (BNTX) stock is a Hold with a $89.00 price target. To see the full list of analyst forecasts on BioNTech SE stock, see the BNTX Stock Forecast page.
Spark’s Take on BNTX Stock
According to Spark, TipRanks’ AI Analyst, BNTX is a Neutral.
The score is held back primarily by deteriorated profitability and bearish technicals (price below major moving averages with negative MACD). Offsetting factors include strong solvency and liquidity with very low leverage, plus a generally constructive earnings update around pipeline progress and strategic de-risking, though near-term guidance points to lower revenues and higher spend.
To see Spark’s full report on BNTX stock, click here.
More about BioNTech SE
BioNTech SE is a Germany-based biotechnology company headquartered in Mainz and known globally for its mRNA-based medicines, including vaccines and immunotherapies. Listed in both Germany and the United States, the company is increasingly focused on oncology, aligning its governance and board expertise with a strategic realignment toward cancer therapeutics and related clinical development and commercialization.
Average Trading Volume: 1,168,307
Technical Sentiment Signal: Sell
Current Market Cap: $22.47B
Find detailed analytics on BNTX stock on TipRanks’ Stock Analysis page.
